Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

8.90USD
18 Aug 2017
Change (% chg)

$0.13 (+1.48%)
Prev Close
$8.77
Open
$8.83
Day's High
$8.93
Day's Low
$8.83
Volume
906
Avg. Vol
18,379
52-wk High
$15.93
52-wk Low
$8.17

RDHL.OQ

Chart for RDHL.OQ

About

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointes... (more)

Overall

No Ratios Available.

Financials

  RDHL.OQ Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -- -- --
ROI: -- 2.87 14.88
ROE: -- 5.20 16.12

BRIEF-Redhill announces U.S. commercialization agreement for FDA-approved gastrointestinal capsules

* Redhill Biopharma announces U.S. Commercialization agreement for FDA-approved GI product esomeprazole strontium delayed-release capsules

Aug 17 2017

BRIEF-‍Redhill Biopharma announces unanimous positive DSMB recommendation for continuation of phase III study with RHB-104 for Crohn's disease​

* ‍Redhill Biopharma announces unanimous positive DSMB recommendation for continuation of phase III study with RHB-104 for Crohn's disease​

Jul 31 2017

BRIEF-Redhill Biopharma reports Q2 loss of $0.06/shr

* Redhill Biopharma reports 2017 second quarter financial results

Jul 25 2017

BRIEF-Redhill Biopharma announces last patient visit in Bekinda phase II study for IBS-D

* Redhill Biopharma announces last patient visit in Bekinda phase II study for IBS-D

Jul 17 2017

BRIEF-Redhill Biopharma announces expected timeline for DSMB meeting

* Redhill Biopharma announces expected timeline for dsmb meeting and provides update on enrollment in the rhb-104 phase iii study for Crohn's disease

Jul 12 2017

BRIEF-RedHill Biopharma confirms initiation of late-stage study on its stomach infection drug

* RedHill biopharma announces confirmatory phase III study initiated with rhb-105 (talicia™) for H. Pylori infection

Jun 15 2017

UPDATE 1-RedHill Bio's gastric drug succeeds in late-stage study

June 14 Israel-based RedHill Biopharma Ltd said its experimental drug for the treatment of gastroenteritis met the main goal in a late-stage study.

Jun 14 2017

BRIEF-Redhill Biopharma announces successful results with Bekinda

* Announces successful phase III top-line results with Bekinda for acute gastroenteritis

Jun 14 2017

RedHill Bio's gastric drug succeeds in late-stage study

June 14 Israel-based RedHill Biopharma Ltd said its experimental drug for the treatment of gastroenteritis met the main goal in a late-stage study.

Jun 14 2017

BRIEF-Redhill Biopharma reports Q1 loss per ordinary share $0.05

* Redhill Biopharma reports 2017 first quarter financial results

May 03 2017

Earnings vs. Estimates